Bharti Airtel BSE 1.57 %, Idea Cellular: Bharti Airtel, Vodafone India and Idea CellularBSE 0.94 % are likely to launch voice over LTE or VoLTE services by the end of September as part of their efforts to upgrade technology and compete better with the new entrant Reliance Jio Infocomm.
Cipla: Pharma major CiplaBSE -2.65 % on Thursday reported a consolidated net loss of Rs 61.79 crore for the quarter ended March 31, 2017. The company had reported net loss of Rs 92.83 crore in the same quarter last year.
GE T&D India: GE T&D, a subsidiary of GE Group, on Thursday posted an increase in net profit to Rs 46.1 crore for the fourth quarter ended March 2017. The company had a profit of Rs 26.9 crore in the same period a year ago.
Thomas Cook: Tour operator Thomas CookBSE 2.40 % reported a loss of Rs 16.42 crore for the fourth quarter ended March 2017. The company had a loss of Rs 23.55 crore in the same period a year ago.
ManappuramBSE 5.46 % Finance: Manappuram Finance, gold loan NBFC, reported a 54 per cent increase in net profit at Rs 200.57 crore for the fourth quarter ended March 2017. It had earned a net profit of Rs 130.70 crore in the same period a year ago.
Dhampur Sugars: The company on Thursday reported a marginal decline in consolidated net profit at Rs 107.27 crore for the quarter ended March 2017. Its net profit stood at Rs 111.82 crore in the year-ago period, the company said in a regulatory filing.
Phillips CarbonBSE 3.97 % Black: The company reported a sharp jump in net profit in the fourth quarter ending March 17′ to Rs 28.14 crore, an over nine-fold growth.
IDBI Bank: Aiming at a turnaround to augment its capital base and recover from bad loans, the IDBI Bank on Thursday said it has initiated the process to sell its non-core assets over a period of time.
HeidelbergCement India: The company’s net profit rose 49.25 per cent to Rs 37.03 crore on 14.05 per cent rise in total income to Rs 542.38 crore in Q4 March 2017 over Q4 March 2016.
Dr Reddy’s Labs: Dr Reddy’s Laboratories said the US health regulator USFDA has issued no observations after inspecting its formulations plant in Andhra Pradesh.